Heidi Taipale1, Anna-Maija Tolppanen2, Marjaana Koponen2, Antti Tanskanen2, Piia Lavikainen2, Reijo Sund2, Jari Tiihonen2, Sirpa Hartikainen2. 1. Kuopio Research Centre of Geriatric Care (Taipale, Koponen, Lavikainen, Hartikainen); School of Pharmacy (Taipale, Tolppanen, Koponen, Lavikainen, Hartikainen); Department of Forensic Psychiatry (Taipale, Tanskanen, Tiihonen), Niuvanniemi Hospital; Institute of Clinical Medicine (Sund); Research Centre for Comparative Effectiveness and Patient Safety (RECEPS) (Tolppanen), University of Eastern Finland, Kuopio, Finland; Department of Clinical Neuroscience (Tanskanen, Tiihonen), Karolinska Institutet, Stockholm, Sweden; National Institute for Health and Welfare (Tanskanen), Helsinki, Finland; Department of Pharmacology (Lavikainen), Drug Development and Therapeutics, University of Turku, Turku, Finland; Department of Social Research (Sund), Centre for Research Methods, University of Helsinki, Helsinki, Finland; Department of Psychiatry (Hartikainen), Kuopio University Hospital, Kuopio, Finland heidi.taipale@uef.fi. 2. Kuopio Research Centre of Geriatric Care (Taipale, Koponen, Lavikainen, Hartikainen); School of Pharmacy (Taipale, Tolppanen, Koponen, Lavikainen, Hartikainen); Department of Forensic Psychiatry (Taipale, Tanskanen, Tiihonen), Niuvanniemi Hospital; Institute of Clinical Medicine (Sund); Research Centre for Comparative Effectiveness and Patient Safety (RECEPS) (Tolppanen), University of Eastern Finland, Kuopio, Finland; Department of Clinical Neuroscience (Tanskanen, Tiihonen), Karolinska Institutet, Stockholm, Sweden; National Institute for Health and Welfare (Tanskanen), Helsinki, Finland; Department of Pharmacology (Lavikainen), Drug Development and Therapeutics, University of Turku, Turku, Finland; Department of Social Research (Sund), Centre for Research Methods, University of Helsinki, Helsinki, Finland; Department of Psychiatry (Hartikainen), Kuopio University Hospital, Kuopio, Finland.
Abstract
BACKGROUND: Knowledge regarding whether benzodiazepines and similarly acting non-benzodiazepines (Z-drugs) are associated with an increased risk of pneumonia among older adults is lacking. We sought to investigate this association among community-dwelling adults with Alzheimer disease, a condition in which both sedative/hypnotic use and pneumonia are common. METHODS: We obtained data on all community-dwelling adults with a recent diagnosis of Alzheimer disease in Finland (2005-2011) from the Medication use and Alzheimer disease (MEDALZ) cohort, which incorporates national registry data on prescriptions, reimbursement, hospital discharges and causes of death. Incident users of benzodiazepines and Z-drugs were identified using a 1-year washout period and matched with nonusers using propensity scores. The association with hospital admission or death due to pneumonia was analyzed with the Cox proportional hazards model and adjusted for use of other psychotropic drugs in a time-dependent manner. RESULTS: Among 49 484 eligible participants with Alzheimer disease, 5232 taking benzodiazepines and 3269 taking Z-drugs were matched 1:1 with those not taking these drugs. Collectively, use of benzodiazepines and Z-drugs was associated with an increased risk of pneumonia (adjusted hazard ratio [HR] 1.22, 95% confidence interval [CI] 1.05-1.42). When analyzed separately, benzodiazepine use was significantly associated with an increased risk of pneumonia (adjusted HR 1.28, 95% CI 1.07-1.54), whereas Z-drug use was not (adjusted HR 1.10, 95% CI 0.84-1.44). The risk of pneumonia was greatest within the first 30 days of benzodiazepine use (HR 2.09, 95% CI 1.26-3.48). INTERPRETATION: Benzodiazepine use was associated with an increased risk of pneumonia among patients with Alzheimer disease. Risk of pneumonia should be considered when weighing the benefits and risks of benzodiazepines in this population.
BACKGROUND: Knowledge regarding whether benzodiazepines and similarly acting non-benzodiazepines (Z-drugs) are associated with an increased risk of pneumonia among older adults is lacking. We sought to investigate this association among community-dwelling adults with Alzheimer disease, a condition in which both sedative/hypnotic use and pneumonia are common. METHODS: We obtained data on all community-dwelling adults with a recent diagnosis of Alzheimer disease in Finland (2005-2011) from the Medication use and Alzheimer disease (MEDALZ) cohort, which incorporates national registry data on prescriptions, reimbursement, hospital discharges and causes of death. Incident users of benzodiazepines and Z-drugs were identified using a 1-year washout period and matched with nonusers using propensity scores. The association with hospital admission or death due to pneumonia was analyzed with the Cox proportional hazards model and adjusted for use of other psychotropic drugs in a time-dependent manner. RESULTS: Among 49 484 eligible participants with Alzheimer disease, 5232 taking benzodiazepines and 3269 taking Z-drugs were matched 1:1 with those not taking these drugs. Collectively, use of benzodiazepines and Z-drugs was associated with an increased risk of pneumonia (adjusted hazard ratio [HR] 1.22, 95% confidence interval [CI] 1.05-1.42). When analyzed separately, benzodiazepine use was significantly associated with an increased risk of pneumonia (adjusted HR 1.28, 95% CI 1.07-1.54), whereas Z-drug use was not (adjusted HR 1.10, 95% CI 0.84-1.44). The risk of pneumonia was greatest within the first 30 days of benzodiazepine use (HR 2.09, 95% CI 1.26-3.48). INTERPRETATION:Benzodiazepine use was associated with an increased risk of pneumonia among patients with Alzheimer disease. Risk of pneumonia should be considered when weighing the benefits and risks of benzodiazepines in this population.
Authors: Peter V Rabins; Deborah Blacker; Barry W Rovner; Teresa Rummans; Lon S Schneider; Pierre N Tariot; David M Blass; John S McIntyre; Sara C Charles; Daniel J Anzia; Ian A Cook; Molly T Finnerty; Bradley R Johnson; James E Nininger; Barbara Schneidman; Paul Summergrad; Sherwyn M Woods; Joseph Berger; C Deborah Cross; Harry A Brandt; Philip M Margolis; John P D Shemo; Barton J Blinder; David L Duncan; Mary Ann Barnovitz; Anthony J Carino; Zachary Z Freyberg; Sheila Hafter Gray; Tina Tonnu; Robert Kunkle; Amy B Albert; Thomas J Craig; Darrel A Regier; Laura J Fochtmann Journal: Am J Psychiatry Date: 2007-12 Impact factor: 18.112
Authors: L Fratiglioni; L J Launer; K Andersen; M M Breteler; J R Copeland; J F Dartigues; A Lobo; J Martinez-Lage; H Soininen; A Hofman Journal: Neurology Date: 2000 Impact factor: 9.910
Authors: James L Rudolph; Nicole M Zanin; Richard N Jones; Edward R Marcantonio; Tamara G Fong; Frances M Yang; Liang Yap; Sharon K Inouye Journal: J Am Geriatr Soc Date: 2010-06-09 Impact factor: 5.562
Authors: Krista L Lanctôt; Nathan Herrmann; Kenneth K Yau; Lyla R Khan; Barbara A Liu; Maysoon M LouLou; Thomas R Einarson Journal: CMAJ Date: 2003-09-16 Impact factor: 8.262
Authors: Kathryn Richardson; George M Savva; Penelope J Boyd; Clare Aldus; Ian Maidment; Eduwin Pakpahan; Yoon K Loke; Antony Arthur; Nicholas Steel; Clive Ballard; Robert Howard; Chris Fox Journal: Health Technol Assess Date: 2021-01 Impact factor: 4.014
Authors: Parker Magin; Amanda Tapley; Adrian J Dunlop; Andrew Davey; Mieke van Driel; Elizabeth Holliday; Simon Morgan; Kim Henderson; Jean Ball; Nigel Catzikiris; Katie Mulquiney; Neil Spike; Rohan Kerr; Simon Holliday Journal: J Gen Intern Med Date: 2018-07-23 Impact factor: 5.128
Authors: Markku Lähteenvuo; Antti Tanskanen; Heidi Taipale; Fabian Hoti; Pia Vattulainen; Eduard Vieta; Jari Tiihonen Journal: JAMA Psychiatry Date: 2018-04-01 Impact factor: 21.596
Authors: Kathryn Richardson; Yoon K Loke; Chris Fox; Ian Maidment; Robert Howard; Nicholas Steel; Antony Arthur; Penelope J Boyd; Clare Aldus; Clive Ballard; George M Savva Journal: BMC Med Date: 2020-11-24 Impact factor: 8.775
Authors: Marc De Hert; Victor Mazereel; Marc Stroobants; Livia De Picker; Kristof Van Assche; Johan Detraux Journal: Front Psychiatry Date: 2022-01-13 Impact factor: 4.157